Molecular profiling reveals frequent gain of MYCN and anaplasia-specific loss of 4q and 14q in Wilms tumor

Genes Chromosomes and Cancer

Volumn 50, Issue 12, 2011, Pages 982-995

  Williams, Richard D ^a   Al Saadi, Reem ^b   Natrajan, Rachael ^b   Mackay, Alan ^b   Chagtai, Tasnim ^a   Little, Suzanne ^b   Hing, Sandra N ^c   Fenwick, Kerry ^b   Ashworth, Alan ^b   Grundy, Paul ^d   Anderson, James R ^e   Dome, Jeffrey S ^f   Perlman, Elizabeth J ^g   Jones, Chris ^b   Pritchard Jones, Kathy ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^d UNIVERSITY OF ALBERTA   (Canada)

^e UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^f CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^g CHILDREN'S MEMORIAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; PROTEIN P53;

ANAPLASTIC CARCINOMA; ARTICLE; DNA MICROARRAY; FEMALE; GENE LOCUS; GENE MUTATION; HUMAN; MALE; MOLECULAR BIOLOGY; MYCN GENE; NEPHROBLASTOMA; ONCOGENE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

ADOLESCENT; ANAPLASIA; CHILD; CHILD, PRESCHOOL; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 14; CHROMOSOMES, HUMAN, PAIR 4; COMPARATIVE GENOMIC HYBRIDIZATION; DNA COPY NUMBER VARIATIONS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INFANT; KIDNEY NEOPLASMS; MALE; MICROARRAY ANALYSIS; NEOPLASM RECURRENCE, LOCAL; NUCLEAR PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; ONCOGENE PROTEINS; SURVIVAL ANALYSIS; WILMS TUMOR;

EID: 80053644624     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.20907     Document Type: Article

References (53)

1. Albert TJ, Molla MN, Muzny DM, Nazareth L, Wheeler D, Song X, Richmond TA, Middle CM, Rodesch MJ, Packard CJ, Weinstock GM, Gibbs RA. 2007. Direct selection of human genomic loci by microarray hybridization. Nat Methods 4: 903-905.
2. Argani P, Collins MH. 2006. Anaplastic nephrogenic rest. Am J Surg Pathol 30: 1339-1341.
3. Bardeesy N, Falkoff D, Petruzzi MJ, Nowak N, Zabel B, Adam M, Aguiar MC, Grundy P, Shows T, Pelletier J. 1994. Anaplastic Wilms' tumor, a subtype displaying poor prognosis, harbours p53 gene mutations. Nat Genet 7: 91-97.
4. Bardeesy N, Beckwith JB, Pelletier J. 1995. Clonal expansion and attenuated apoptosis in Wilms' tumors are associated with p53 gene mutations. Cancer Res 55: 215-219.
5. Beckwith JB, Palmer NF. 1978. Histopathology and prognosis of Wilms tumors: Results from the First National Wilms' Tumor Study. Cancer 41: 1937-1948.
6. Breslow N, Olshan A, Beckwith JB, Green DM. 1993. Epidemiology of Wilms tumor. Med Pediatr Oncol 21: 172-181.
7. Breslow NE, Ou SS, Beckwith JB, Haase GM, Kalapurakal JA, Ritchey ML, Shamberger RC, Thomas PR, D'Angio GJ, Green DM. 2004. Doxorubicin for favorable histology, Stage II-III Wilms tumor: Results from the National Wilms Tumor Studies. Cancer 101: 1072-1080.
8. Brodeur GM. 2003. Neuroblastoma: Biological insights into a clinical enigma. Nat Rev Cancer 3: 203-216.
9. Coe BP, Ylstra B, Carvalho B, Meijer GA, Macaulay C, Lam WL. 2007. Resolving the resolution of array CGH. Genomics 89: 647-653.
10. de Kraker J, Graf N, van Tinteren H, Pein F, Sandstedt B, Godzinski J, Tournade MF. 2004. Reduction of postoperative chemotherapy in children with stage I intermediate-risk and anaplastic Wilms' tumor (SIOP 93-01 trial): A randomised controlled trial. Lancet 364: 1229-1235.
11. Dome JS, Cotton CA, Perlman EJ, Breslow NE, Kalapurakal JA, Ritchey ML, Grundy PE, Malogolowkin M, Beckwith JB, Shamberger RC, Haase GM, Coppes MJ, Coccia P, Kletzel M, Weetman RM, Donaldson M, Macklis RM, Green DM. 2006. Treatment of anaplastic histology Wilms' tumor: Results from the fifth National Wilms' Tumor Study. J Clin Oncol 24: 2352-2358.
12. el Bahtimi R, Hazen-Martin DJ, Re GG, Willingham MC, Garvin AJ. 1996. Immunophenotype, mRNA expression, and gene structure of p53 in Wilms' tumors. Mod Pathol 9: 238-244.
13. Faria P, Beckwith JB, Mishra K, Zuppan C, Weeks DA, Breslow N, Green DM. 1996. Focal versus diffuse anaplasia in Wilms tumor-New definitions with prognostic significance: A report from the National Wilms Tumor Study Group. Am J Surg Pathol 20: 909-920.
14. Gow KW, Murphy JJ. 2002. Cytogenetic and histologic findings in Wilms' tumor. J Pediatr Surg 37: 823-827.
15. Green DM. 2004. The treatment of stages I-IV favorable histology Wilms' tumor. J Clin Oncol 22: 1366-1372.
16. Green DM, Breslow NE, Beckwith JB, Finklestein JZ, Grundy PE, Thomas PR, Kim T, Shochat SJ, Haase GM, Ritchey ML, Kelalis PP, D'Angio GJ. 1998. Comparison between single-dose and divided-dose administration of dactinomycin and doxorubicin for patients with Wilms' tumor: A report from the National Wilms' Tumor Study Group. J Clin Oncol 16: 237-245.
17. Green DM, Breslow NE, Beckwith JB, Ritchey ML, Shamberger RC, Haase GM, D'Angio GJ, Perlman E, Donaldson M, Grundy PE, Weetman R, Coppes MJ, Malogolowkin M, Shearer P, Coccia P, Kletzel M, Thomas PR, Macklis R, Tomlinson G, Huff V, Newbury R, Weeks D. 2001. Treatment with nephrectomy only for small, stage I/favorable histology Wilms' tumor: A report from the National Wilms' Tumor Study Group. J Clin Oncol 19: 3719-3724.
18. Grundy PE, Breslow NE, Li S, Perlman E, Beckwith JB, Ritchey ML, Shamberger RC, Haase GM, D'Angio GJ, Donaldson M, Coppes MJ, Malogolowkin M, Shearer P, Thomas PR, Macklis R, Tomlinson G, Huff V, Green DM. 2005. Loss of heterozygosity for chromosomes 1p and 16q is an adverse prognostic factor in favorable-histology Wilms tumor: A report from the National Wilms Tumor Study Group. J Clin Oncol 23: 7312-7321.
19. Hegde P, Qi R, Abernathy K, Gay C, Dharap S, Gaspard R, Hughes JE, Snesrud E, Lee N, Quackenbush J. 2000. A concise guide to cDNA microarray analysis. Biotechniques 29: 548-562.
20. Hill DA, Shear TD, Liu T, Billups CA, Singh PK, Dome JS. 2003. Clinical and biologic significance of nuclear unrest in Wilms tumor. Cancer 97: 2318-2326.
21. Hodges E, Xuan Z, Balija V, Kramer M, Molla MN, Smith SW, Middle CM, Rodesch MJ, Albert TJ, Hannon GJ, McCombie WR. 2007. Genome-wide in situ exon capture for selective resequencing. Nat Genet 39: 1522-1527.
22. Klamt B, Schulze M, Thate C, Mares J, Goetz P, Kodet R, Scheulen W, Weirich A, Graf N, Gessler M. 1998. Allele loss in Wilms tumors of chromosome arms 11q, 16q, and 22q correlate with clinicopathological parameters. Genes Chromosomes Cancer 22: 287-294.
23. Lahoti C, Thorner P, Malkin D, Yeger H. 1996. Immunohistochemical detection of p53 in Wilms' tumors correlates with unfavorable outcome. Am J Pathol 148: 1577-1589.
24. Li W, Kessler P, Williams BR. 2005. Transcript profiling of Wilms tumors reveals connections to kidney morphogenesis and expression patterns associated with anaplasia. Oncogene 24: 457-468.
25. Malkin D, Sexsmith E, Yeger H, Williams BR, Coppes MJ. 1994. Mutations of the p53 tumor suppressor gene occur infrequently in Wilms' tumor. Cancer Res 54: 2077-2079.
26. Mares J, Leskova V, Sedlacek Z, Marikova T, Bocek P, Kodet R, Goetz P. 1996. [Amplification of oncogenes in solid tumors in children]. Cas Lek Cesk 135: 493-496.
27. McQuaid S, O'Meara A. 1990. N-myc oncogene amplification in paediatric tumors. Ir J Med Sci 159: 172-174.
28. Messahel B, Williams R, Ridolfi A, A'Hern R, Warren W, Tinworth L, Hobson R, Al-Saadi R, Whyman G, Brundler MA, Kelsey A, Sebire N, Jones C, Vujanic G, Pritchard-Jones K. 2009. Allele loss at 16q defines poorer prognosis Wilms tumor irrespective of treatment approach in the UKW1-3 clinical trials: A Children's Cancer and Leukaemia Group (CCLG) Study. Eur J Cancer 45: 819-826.
29. Mitchell C, Pritchard-Jones K, Shannon R, Hutton C, Stevens S, Machin D, Imeson J, Kelsey A, Vujanic GM, Gornall P, Walker J, Taylor R, Sartori P, Hale J, Levitt G, Messahel B, Middleton H, Grundy R, Pritchard J. 2006. Immediate nephrectomy versus preoperative chemotherapy in the management of non-metastatic Wilms' tumor: Results of a randomised trial (UKW3) by the UK Children's Cancer Study Group. Eur J Cancer 42: 2554-2562.
30. Natrajan R, Williams RD, Hing SN, Mackay A, Reis-Filho JS, Fenwick K, Iravani M, Valgeirsson H, Grigoriadis A, Langford CF, Dovey O, Gregory SG, Weber BL, Ashworth A, Grundy PE, Pritchard-Jones K, Jones C. 2006. Array CGH profiling of favourable histology Wilms tumors reveals novel gains and losses associated with relapse. J Pathol 210: 49-58.
31. Natrajan R, Williams RD, Grigoriadis A, Mackay A, Fenwick K, Ashworth A, Dome JS, Grundy PE, Pritchard-Jones K, Jones C. 2007. Delineation of a 1Mb breakpoint region at 1p13 in Wilms tumors by fine-tiling oligonucleotide array CGH. Genes Chromosomes Cancer 46: 607-615.
32. Nisen PD, Zimmerman KA, Cotter SV, Gilbert F, Alt FW. 1986. Enhanced expression of the N-myc gene in Wilms' tumors. Cancer Res 46: 6217-6222.
33. Norris MD, Brian MJ, Vowels MR, Stewart BW. 1988. N-myc amplification in Wilms' tumor. Cancer Genet Cytogenet 30: 187-189.
34. Pavlidis P, Lewis DP, Noble WS. 2002. Exploring gene expression data with class scores. Pac Symp Biocomput 2002: 474-485.
35. Peres EM, Savasan S, Cushing B, Abella S, Mohamed AN. 2004. Chromosome analyses of 16 cases of Wilms tumor: Different pattern in unfavorable histology. Cancer Genet Cytogenet 148: 66-70.
36. Pritchard-Jones K, Kelsey A, Vujanic G, Imeson J, Hutton C, Mitchell C. 2003. Older age is an adverse prognostic factor in stage I, favorable histology Wilms' tumor treated with vincristine monochemotherapy: A study by the United Kingdom Children's Cancer Study Group, Wilm's Tumor Working Group. J Clin Oncol 21: 3269-3275.
37. Reinhard H, Semler O, Burger D, Bode U, Flentje M, Gobel U, Gutjahr P, Leuschner I, Maass E, Niggli F, Scheel-Walter HG, Stockle M, Thuroff JW, Troger J, Weirich A, von Schweinitz D, Zoubek A, Graf N. 2004. Results of the SIOP 93-01/GPOH trial and study for the treatment of patients with unilateral nonmetastatic Wilms Tumor. Klin Padiatr 216: 132-140.
38. Schaub R, Burger A, Bausch D, Niggli FK, Schafer BW, Betts DR. 2007. Array comparative genomic hybridization reveals unbalanced gain of the MYCN region in Wilms tumors. Cancer Genet Cytogenet 172: 61-65.
39. Shaw AP, Poirier V, Tyler S, Mott M, Berry J, Maitland NJ. 1988. Expression of the N-myc oncogene in Wilms' tumor and related tissues. Oncogene 3: 143-149.
40. Stock C, Ambros IM, Lion T, Zoubek A, Amann G, Gadner H, Ambros PF. 2002. Genetic changes of two Wilms tumors with anaplasia and a review of the literature suggesting a marker profile for therapy resistance. Cancer Genet Cytogenet 135: 128-138.
41. Takeuchi S, Bartram CR, Ludwig R, Royer-Pokora B, Schneider S, Imamura J, Koeffler HP. 1995. Mutations of p53 in Wilms' tumors. Mod Pathol 8: 483-487.
42. Tewhey R, Nakano M, Wang X, Pabon-Pena C, Novak B, Giuffre A, Lin E, Happe S, Roberts DN, LeProust EM, Topol EJ, Harismendy O, Frazer KA. 2009. Enrichment of sequencing targets from the human genome by solution hybridization. Genome Biol 10: R116.
43. Tournade MF, Com-Nougue C, de Kraker J, Ludwig R, Rey A, Burgers JM, Sandstedt B, Godzinski J, Carli M, Potter R, Zucker JM. 2001. Optimal duration of preoperative therapy in unilateral and nonmetastatic Wilms' tumor in children older than 6 months: Results of the Ninth International Society of Pediatric Oncology Wilms' Tumor Trial and Study. J Clin Oncol 19: 488-500.
44. Vujanic GM, Harms D, Sandstedt B, Weirich A, de Kraker J, Delemarre JF. 1999. New definitions of focal and diffuse anaplasia in Wilms tumor: The International Society of Paediatric Oncology (SIOP) experience. Med Pediatr Oncol 32: 317-323.
45. Vujanic GM, Sandstedt B, Harms D, Kelsey A, Leuschner I, de Kraker J. 2002. Revised International Society of Paediatric Oncology (SIOP) working classification of renal tumors of childhood. Med Pediatr Oncol 38: 79-82.
46. Weirich A, Ludwig R, Graf N, Abel U, Leuschner I, Vujanic GM, Mehls O, Boos J, Beck J, Royer-Pokora B, Voute PA. 2004. Survival in nephroblastoma treated according to the trial and study SIOP-9/GPOH with respect to relapse and morbidity. Ann Oncol 15: 808-820.
47. Williams RD, Hing SN, Greer BT, Whiteford CC, Wei JS, Natrajan R, Kelsey A, Rogers S, Campbell C, Pritchard-Jones K, Khan J. 2004. Prognostic classification of relapsing favorable histology Wilms tumor using cDNA microarray expression profiling and support vector machines. Genes Chromosomes Cancer 41: 65-79.
48. Williams RD, Al-Saadi R, Chagtai T, Popov S, Messahel B, Sebire N, Gessler M, Wegert J, Graf N, Leuschner I, Hubank M, Jones C, Vujanic G, Pritchard-Jones K. 2010. Subtype-specific FBXW7 mutation and MYCN copy number gain in Wilms' tumor. Clin Cancer Res 16: 2036-2045.
49. Williamson D, Lu YJ, Gordon T, Sciot R, Kelsey A, Fisher C, Poremba C, Anderson J, Pritchard-Jones K, Shipley J. 2005. Relationship between MYCN copy number and expression in rhabdomyosarcomas and correlation with adverse prognosis in the alveolar subtype. J Clin Oncol 23: 880-888.
50. Wittmann S, Zirn B, Alkassar M, Ambros P, Graf N, Gessler M. 2007. Loss of 11q and 16q in Wilms tumors is associated with anaplasia, tumor recurrence, and poor prognosis. Genes Chromosomes Cancer 46: 163-170.
51. Wittmann S, Wunder C, Zirn B, Furtwangler R, Wegert J, Graf N, Gessler M. 2008. New prognostic markers revealed by evaluation of genes correlated with clinical parameters in Wilms tumors. Genes Chromosomes Cancer 47: 386-395.
52. Yeh A, Wei M, Golub SB, Yamashiro DJ, Murty VV, Tycko B. 2002. Chromosome arm 16q in Wilms tumors: Unbalanced chromosomal translocations, loss of heterozygosity, and assessment of the CTCF gene. Genes Chromosomes Cancer 35: 156-163.
53. Zirn B, Hartmann O, Samans B, Krause M, Wittmann S, Mertens F, Graf N, Eilers M, Gessler M. 2006. Expression profiling of Wilms tumors reveals new candidate genes for different clinical parameters. Int J Cancer 118: 1954-1962.